Nuropod has introduced its wearable vagus nerve stimulation device to the U.S. market, offering a noninvasive approach to nervous system support built on a proprietary AVNT™ waveform and more than a decade of research and development.
Sacramento, United States, September 11, 2026 /PressCable/ -- Nuropod, a wearable vagus nerve stimulation device for nervous system support, has been announced for consumers in the United States. It is a scientifically validated wearable neurotechnology device designed to support the nervous system by delivering gentle electrical pulses through the skin to a branch of the vagus nerve at the tragus, where the vagus nerve reaches the skin of the ear. The device is intended to fit easily into everyday routines, with most people using it for around 30 minutes once or twice a day while working, reading, or watching television.
More information is available at https://nuropod.com/pages/how-it-works
The announcement comes at a time when more consumers are looking for research-backed ways to support their nervous system as part of their everyday wellness routine. Wearable technologies have made it easier to access noninvasive approaches outside clinical settings, while growing awareness of the vagus nerve has encouraged more people to explore how it influences the body's response to stress, rest, and recovery.
Nuropod uses AVNT™ (Adaptive Vagus Neuromodulation Technology), its patented waveform, to deliver gentle electrical pulses through an earpiece placed on the tragus. This is where the vagus nerve reaches the skin of the ear. The same noninvasive method has been used in hospitals and research settings, while Nuropod is offered as a consumer wellness device in the United States. It is FCC compliant and is not a medical device.
Nuropod is built on 10+ years of research and development. The technology is supported by 60+ completed clinical studies, 100+ ongoing clinical studies, and 150+ research partners. It has been used in 5M+ user sessions, is trusted by 1,000+ healthcare professionals, and is supported by peer-reviewed research.
Nuropod is designed to be used alongside existing care, not as a replacement for it. People experiencing persistent symptoms or living with a health condition should consult a qualified healthcare professional before use. The device is available directly to consumers in the United States.
To learn more about Nuropod, its research-backed wearable vagus nerve stimulation technology, and the science behind its patented AVNT™ waveform, visit https://nuropod.com/pages/how-it-works
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-designated risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: Victor Kho
Email: Send Email
Organization: Nuropod
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Source: PressCable
Release ID: 89203076
If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.
